ATE374642T1 - Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose - Google Patents
Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenoseInfo
- Publication number
- ATE374642T1 ATE374642T1 AT01966399T AT01966399T ATE374642T1 AT E374642 T1 ATE374642 T1 AT E374642T1 AT 01966399 T AT01966399 T AT 01966399T AT 01966399 T AT01966399 T AT 01966399T AT E374642 T1 ATE374642 T1 AT E374642T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- treat stenosis
- migration
- specific
- smooth muscle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22967900P | 2000-09-01 | 2000-09-01 | |
US26551601P | 2001-01-31 | 2001-01-31 | |
US09/940,101 US20020119148A1 (en) | 2000-09-01 | 2001-08-27 | ErbB4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE374642T1 true ATE374642T1 (de) | 2007-10-15 |
Family
ID=27397993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01966399T ATE374642T1 (de) | 2000-09-01 | 2001-08-29 | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose |
Country Status (12)
Country | Link |
---|---|
US (6) | US20020119148A1 (de) |
EP (1) | EP1351744B1 (de) |
JP (1) | JP2004507559A (de) |
AT (1) | ATE374642T1 (de) |
AU (2) | AU8691801A (de) |
CA (1) | CA2420062C (de) |
DE (1) | DE60130797T2 (de) |
DK (1) | DK1351744T3 (de) |
ES (1) | ES2295202T3 (de) |
HK (1) | HK1059404A1 (de) |
IL (2) | IL154495A0 (de) |
WO (1) | WO2002018444A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US20040156835A1 (en) * | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
WO2003101401A2 (en) * | 2002-06-03 | 2003-12-11 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
PL214010B1 (pl) | 2002-07-15 | 2013-06-28 | Genentech Inc | Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala |
US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
JP4527388B2 (ja) * | 2003-12-11 | 2010-08-18 | 東洋鋼鈑株式会社 | ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法 |
TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
AU2006220719A1 (en) * | 2005-03-07 | 2006-09-14 | Ligacept, Llc | Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease |
RS53042B (en) | 2007-02-16 | 2014-04-30 | Merrimack Pharmaceuticals Inc. | ANTIBODIES AGAINST ERBB3 AND THEIR USES |
JP2011516423A (ja) | 2008-03-28 | 2011-05-26 | シー レーン バイオテクノロジーズ, エルエルシー | ウイルス抗原に対する中和分子 |
US8623592B2 (en) * | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
WO2010068437A1 (en) | 2008-11-25 | 2010-06-17 | Genentech, Inc. | Isoform specific anti-her4 antibodies |
CN102356092B (zh) * | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
EP2501817B2 (de) | 2010-02-08 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Maus mit gemeinen leichten ketten |
WO2011107100A1 (en) | 2010-03-03 | 2011-09-09 | Aarhus Universitet | Methods and compositions for regulation of herv4 |
SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
EP2640831A1 (de) | 2010-11-17 | 2013-09-25 | Sea Lane Biotechnologies,llc. | Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel |
NZ781020A (en) | 2011-08-05 | 2023-01-27 | Regeneron Pharma | Humanized universal light chain mice |
KR20140054268A (ko) | 2011-08-26 | 2014-05-08 | 메리맥 파마슈티컬즈, 인크. | 탠덤 fc 이중특이적 항체 |
EP2917243B1 (de) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Die beta-haarnadel von her3 bindende her3-antikörper |
US9725511B2 (en) * | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 |
TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗C-MET串聯Fc雙特異性抗體 |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
FR3020063A1 (fr) * | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
CA2944895A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0444961A1 (de) | 1990-03-02 | 1991-09-04 | Bristol-Myers Squibb Company | Her3: Ein neues EGF-Rezeptor Homologes |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
GEP20012444B (en) * | 1994-11-14 | 2001-05-25 | Warner Lambert Company Us | 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation |
US5770567A (en) * | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
WO1998002541A1 (en) * | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Gamma-heregulin |
NZ333325A (en) * | 1996-07-12 | 2000-06-23 | Genentech Inc | Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors |
ATE371673T1 (de) * | 1996-11-27 | 2007-09-15 | Genentech Inc | Affinitätsreinigung von polypeptiden an einer protein a-matrix |
US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
US6994856B1 (en) * | 1997-07-24 | 2006-02-07 | Genentech, Inc. | ErbB4 receptor-specific neuregulin related ligands and uses therefor |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
CZ20011759A3 (cs) | 1998-11-19 | 2002-01-16 | Warner-Lambert Company | N-[4-(3-chlor-4-fluor-fenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl]-akrylamid, ireversibilní inhibitor tyrosin-kinas |
CA2412377A1 (en) * | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
-
2001
- 2001-08-27 US US09/940,101 patent/US20020119148A1/en not_active Abandoned
- 2001-08-29 JP JP2002523958A patent/JP2004507559A/ja active Pending
- 2001-08-29 DK DK01966399T patent/DK1351744T3/da active
- 2001-08-29 ES ES01966399T patent/ES2295202T3/es not_active Expired - Lifetime
- 2001-08-29 US US10/362,380 patent/US7332579B2/en not_active Expired - Fee Related
- 2001-08-29 AU AU8691801A patent/AU8691801A/xx active Pending
- 2001-08-29 DE DE60130797T patent/DE60130797T2/de not_active Expired - Lifetime
- 2001-08-29 AT AT01966399T patent/ATE374642T1/de active
- 2001-08-29 EP EP01966399A patent/EP1351744B1/de not_active Expired - Lifetime
- 2001-08-29 WO PCT/US2001/026984 patent/WO2002018444A2/en active IP Right Grant
- 2001-08-29 CA CA2420062A patent/CA2420062C/en not_active Expired - Fee Related
- 2001-08-29 AU AU2001286918A patent/AU2001286918B2/en not_active Ceased
- 2001-08-29 IL IL15449501A patent/IL154495A0/xx unknown
-
2003
- 2003-02-17 IL IL154495A patent/IL154495A/en not_active IP Right Cessation
-
2004
- 2004-03-27 HK HK04102271A patent/HK1059404A1/xx not_active IP Right Cessation
-
2005
- 2005-10-11 US US11/248,122 patent/US20060093603A1/en not_active Abandoned
-
2006
- 2006-10-13 US US11/581,221 patent/US20070092513A1/en not_active Abandoned
-
2008
- 2008-06-24 US US12/215,200 patent/US7704498B2/en not_active Expired - Fee Related
-
2010
- 2010-04-02 US US12/753,792 patent/US20100190964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060093603A1 (en) | 2006-05-04 |
US7332579B2 (en) | 2008-02-19 |
US20020119148A1 (en) | 2002-08-29 |
AU8691801A (en) | 2002-03-13 |
US20090068205A1 (en) | 2009-03-12 |
WO2002018444A3 (en) | 2003-07-31 |
DE60130797D1 (de) | 2007-11-15 |
IL154495A (en) | 2009-12-24 |
US20040052786A1 (en) | 2004-03-18 |
EP1351744A2 (de) | 2003-10-15 |
IL154495A0 (en) | 2003-09-17 |
HK1059404A1 (en) | 2004-07-02 |
WO2002018444A2 (en) | 2002-03-07 |
CA2420062A1 (en) | 2002-03-07 |
US20070092513A1 (en) | 2007-04-26 |
EP1351744B1 (de) | 2007-10-03 |
US7704498B2 (en) | 2010-04-27 |
AU2001286918B2 (en) | 2006-12-21 |
DE60130797T2 (de) | 2008-08-07 |
DK1351744T3 (da) | 2008-02-11 |
US20100190964A1 (en) | 2010-07-29 |
CA2420062C (en) | 2014-04-01 |
ES2295202T3 (es) | 2008-04-16 |
JP2004507559A (ja) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE374642T1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE69528475T2 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE494388T1 (de) | Neues verfahren zum erschaffen von proteinkinase- inhibitoren | |
ATE376446T1 (de) | Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung | |
ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
DE60139457D1 (de) | Ungen unter verwendung einer geweberisikokarte | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
DE69737397D1 (de) | Verwendung von mif-antagonisten zur krebstherapie | |
ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE60033576D1 (de) | Methoden zum screening knochenmorphogenetishemimetika | |
DE602004004883D1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
ATE501730T1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten | |
ATE239497T1 (de) | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen | |
DE69827387D1 (de) | Verwendung von pramipexol zur behandlung von restless-legs-syndrom | |
ATE409732T1 (de) | Methoden zur vorbehandlung von schuhen | |
ATE474939T1 (de) | Verfahren zum behandeln von leder | |
DE60007864D1 (de) | Verwendung von antileukoprotease zur behandlung von endometriose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1351744 Country of ref document: EP |